Table 2.
Univariable and Multivariable Cox Proportional Hazard Analysis for Overall Survival
| Prognostic Factor | Hazard Ratio (95% CI) | |||
|---|---|---|---|---|
| Univariable | P Value | Multivariable | P Value | |
| KRAS | ||||
| Wild type | 1 [Reference] | 1 [Reference] | ||
| All codon 12 mutants | 1.54 (1.05–2.27) | .03 | 1.7 (1.13–2.55) | .01 |
| All codon 13 mutants | 1.47 (0.83–2.62) | .19 | 1.61 (0.87–2.97) | .13 |
| Age | 1.01 (0.99–1.02) | .38 | … | … |
| Female | 1.11 (0.80–1.54) | .52 | … | … |
| AJCC 7th edition T stage | ||||
| T1/T2 | 1 [Reference] | |||
| T3/T4 | 1 (0.62–1.60) | .99 | … | … |
| Location of tumor | ||||
| Colon | 1 [Reference] | |||
| Rectal | 1.08 (0.76–1.52) | .67 | … | … |
| Disease-free interval <12 mo | 1.06 (0.76–1.48) | .74 | … | … |
| Regional lymph node status | ||||
| Negative | 1 [Reference] | 1 [Reference] | ||
| Positive | 1.8 (1.24–2.62) | <.001 | 2.06 (1.39–3.04) | <.001 |
| Tumor size | 1.06 (0.97–1.15) | .20 | ||
| No. of lesions | 1.07 (0.99–1.15) | .09 | … | … |
| Bilobar lesions | 1.06 (0.75–1.50) | .75 | … | … |
| CEA ≥ 30 ng/mL | 1.00 (1.00–1.00) | NA | … | … |
| Chemotherapy | ||||
| Preoperative | 1.19 (0.82–1.74) | .36 | … | … |
| Adjuvant | 0.84 (0.61–1.17) | .30 | … | … |
| Ablation | 1.54 (1.08–2.20) | .02 | 1.81 (1.25–2.62) | .002 |
| Margin | ||||
| R0 | 1 [Reference] | 1 [Reference] | ||
| R1 | 1.55 (1.09–2.21) | .02 | 1.73 (1.17–2.57) | .01 |
Abbreviations: AJCC, American Joint Committee on Cancer; CEA, carcinoembryonic antigen; NA, not applicable; ellipses, not included in the multivariable analysis.